Long-term proliferation of functional human NK cells, with conversion of CD56 dim NK cells to a CD56 bright phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12

Cancer Immunology, Immunotherapy

Volumn 61, Issue 5, 2012, Pages 615-628

  Dowell, Alexander C ^a   Oldham, Kimberley A ^a   Bhatt, Rupesh I ^b   Lee, Steven P ^a   Searle, Peter F ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

4 1BB (CD137); 4 1BBL (CD137L); IL 12; NK cells; Ovarian cancer; Renal cell carcinoma

Indexed keywords

CD137 LIGAND; CD16 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTRANSFORMATION; CANCER CELL CULTURE; CELL ACTIVATION; CELL FUNCTION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; NATURAL KILLER CELL; OVARY CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TARGET CELL;

4-1BB LIGAND; ANTIGENS, CD56; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GPI-LINKED PROTEINS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NEOPLASMS; PHENOTYPE; RECEPTORS, IGG; UP-REGULATION;

EID: 84862487272     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1122-3     Document Type: Article

References (40)

1. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100. doi:10.1126/science. 1068440295/5562/2097 (Pubitemid 34229476)
2. Imai C, Iwamoto S, Campana D (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106:376-383. doi:10.1182/blood-2004-12-4797 (Pubitemid 40967217)
3. Baessler T, Charton JE, Schmiedel BJ, Grunebach F, Krusch M, Wacker A, Rammensee HG, Salih HR (2010) CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 115:3058-3069. doi:10.1182/blood-2009- 06-227934
4. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633-640 (Pubitemid 33043908)
5. Wendt K, Wilk E, Buyny S, Buer J, Schmidt RE, Jacobs R (2006) Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells. J Leukoc Biol 80:1529-1541. doi:10.1189/jlb.0306191 (Pubitemid 44904992)
6. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503-510. doi:10.1038/ni1582 (Pubitemid 351560519)
7. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J (2009) CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126:458-465. doi:10.1111/j.1365-2567.2008.03027.x
8. Nagler A, Lanier LL, Cwirla S, Phillips JH (1989) Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 143:3183-3191 (Pubitemid 20010143)
9. Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, McMichael A, Enver T, Bowness P (2007) CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 179:89-94 (Pubitemid 46986521)
10. Beziat V, Descours B, Parizot C, Debre P, Vieillard V (2010) NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS One 5:e11966. doi:10.1371/journal.pone.0011966
11. Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, Morandi B, Ferlazzo G, Thiel A, Schmitt-Knosalla I, Romagnani C (2010) CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 116:1299-1307. doi:10.1182/blood-2009-11-253286
12. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL (2010) CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16 ? NK-cell subset. Blood 116:3865-3874. doi:10.1182/blood-2010-04-282301
13. Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK, Liu S, McClory S, Marcucci G, Trotta R, Caligiuri MA (2010) CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 115:274-281. doi:10.1182/blood-2009-04-215491
14. Alderson MR, Smith CA, Tough TW, Davis-Smith T, Armitage RJ, Falk B, Roux E, Baker E, Sutherland GR, Din WS (1994) Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 24:2219-2227. doi:10.1002/eji.1830240943 (Pubitemid 24276559)
15. Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, Watts TH (2001) 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T Cells with similar efficacy. J Immunol 167:1313-1324 (Pubitemid 32703127)
16. Habib-Agahi M, Phan TT, Searle PF (2007) Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int Immunol 19:1383-1394. doi:10.1093/intimm/dxm106 (Pubitemid 350131344)
17. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682-685 (Pubitemid 27264981)
18. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L (1998) Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 28:1116-1121. doi:10.1002/(SICI)1521-4141(199803)28:03\1116::AID-IMMU1116[3.0. CO;2-A (Pubitemid 28116225)
19. Sznol M, Hodi FS, Margolin K, McDermott DF, Emstoff M, Kirkwood J, Wojtaszek C, Feltquate D, Logan T (2008) Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol 26(suppl) (abstr 3007). http://www.asco.org/ascov2/ Meetings/Abstracts?&vmview=abst-detail-view&confID=55&abstractID= 35273
20. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L (1998) NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 190:167-172. doi:10.1006/cimm.1998.1396 (Pubitemid 29011104)
21. Chen SH, Pham-Nguyen KB, Martinet O, Huang Y, Yang W, Thung SN, Chen L, Mittler R, Woo SL (2000) Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol Ther 2:39-46. doi:10.1006/mthe.2000.0086S1525-0016(00)90086-8
22. Martinet O, Ermekova V, Qiao JQ, Sauter B, Mandeli J, Chen L, Chen SH (2000) Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. J Natl Cancer Inst 92:931-936 (Pubitemid 30429194)
23. Xu D, Gu P, Pan PY, Li Q, Sato AI, Chen SH (2004) NK and CD8 + T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 109:499-506. doi:10.1002/ijc.11696 (Pubitemid 38339639)
24. Huang JH, Zhang SN, Choi KJ, Choi IK, Kim JH, Lee MG, Kim H, Yun CO (2010) Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther 18:264-274. doi:10.1038/mt.2009.205
25. Lin W, Voskens CJ, Zhang X, Schindler DG, Wood A, Burch E, Wei Y, Chen L, Tian G, Tamada K, Wang LX, Schulze DH, Mann D, Strome SE (2008) Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies. Blood 112:699-707. doi: 10.1182/blood-2007-11-122465
26. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781. doi:10.1016/j.ejca.2009.12.014
27. Reeves DJ, Liu CY (2009) Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 64:11-25. doi:10.1007/s00280-009-0983-z
28. Rini BI (2009) Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 27:3225-3234. doi:10.1200/JCO.2008.19.9836
29. Sparrow RL, Tippett E (2005) Discrimination of live and early apoptotic mononuclear cells by the fluorescent SYTO 16 vital dye. J Immunol Methods 305:173-187. doi:10.1016/j.jim.2005.07.017 (Pubitemid 41416712)
30. Wendel M, Galani IE, Suri-Payer E, Cerwenka A (2008) Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 68:8437-8445. doi:10.1158/0008-5472.CAN-08-1440
31. Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S, Konishi I (2009) Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 58:641-652. doi:10.1007/s00262-008- 0585-3
32. Lyons AB (2000) Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 243:147-154
33. Lee H-W, Park S-J, Choi BK, Kim HH, Nam K-O, Kwon BS (2002) 4-1BB promotes the survival of CD8 + T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 169:4882-4888 (Pubitemid 35217152)
34. Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM (2009) Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci USA 106:1915-1919. doi:10.1073/pnas.0813192106
35. Sun JC, Beilke JN, Lanier LL (2009) Adaptive immune features of natural killer cells. Nature 457:557-561. doi:10.1038/nature07665
36. Horowitz A, Behrens RH, Okell L, Fooks AR, Riley EM (2010) NK cells as effectors of acquired immune responses: effector CD4 + T cell-dependent activation of NK cells following vaccination. J Immunol 185:2808-2818. doi:10.4049/jimmunol.1000844
37. Croft M (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3:609-620. doi:10.1038/nri1148nri1148
38. Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, Chapoval AI (2010) Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 116:1726-1733. doi:10.1182/blood- 2009-07-234211
39. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D (2009) Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 69:4010-4017. doi:10.1158/0008-5472. CAN-08-3712
40. Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P (2008) MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 112:2369-2380. doi:10.1182/blood-2008-03-143727